This webinar highlights the key considerations and applications of next-generation sequencing for managing non-small cell lung cancer patients using plasma-based approaches. 

NSCLC is the most common type of lung cancer, accounting for about 80 percent of all lung cancer cases. Approximately 35 percent of NSCLC patients do not have sufficient tissue biopsy material for informative NGS testing due to late-stage diagnosis and difficulties associated with repeat biopsy for real-time monitoring. 

Circulating free DNA (cfDNA) has been proposed as an alternative approach for the detection of actionable mutations in NSCLC. Recent advances in next-generation sequencing of plasma allow for the rapid and affordable identification of driver mutations in NSCLC patients, which have a profound impact on clinical management. 

This online seminar will detail the clinical considerations of NGS-based plasma testing for managing NSCLC patients.